Harmony Biosciences (NASDAQ:HRMY) Stock Price Breaks Below 200-Day Moving Average After Earnings Miss

Posted by Brenda Bartman on Nov 5th, 2026

Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY – Get Free Report) passed below its 200-day moving average during trading on Wednesday following a weaker than expected earnings announcement. The stock has a 200-day moving average of $34.73 and traded as low as $32.61. Harmony Biosciences shares last traded at $34.4650, with a volume of 2,469,132 shares traded.

The company reported $0.81 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.09 by ($0.28). The business had revenue of $268.92 million during the quarter, compared to analysts’ expectations of $272.05 million. Harmony Biosciences had a return on equity of 20.06% and a net margin of 18.88%. The firm’s revenue was up 12.3% on a year-over-year basis. During the same period in the prior year, the company posted $1.08 earnings per share.

Trending Headlines about Harmony Biosciences

Here are the key news stories impacting Harmony Biosciences this week:

Positive Sentiment: WAKIX generated $269 million in third-quarter net revenue, supported by 400 net patient additions. Harmony reiterated its full-year WAKIX revenue guidance of $1.0 billion to $1.04 billion and said it remains on track to exceed $1 billion. The company also reported strong multiple-ascending-dose data for orexin agonist BP-205, supporting its potential best-in-class profile. Company earnings release
Negative Sentiment: Quarterly adjusted earnings of $0.81 per share missed the $1.09 analyst consensus, while revenue of $268.92 million came in below estimates of $272.05 million. Revenue was up 12.3% year over year, but the earnings miss was the clearest near-term headwind for the stock. Quarterly results

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the stock. LADENBURG THALM/SH SH initiated coverage on shares of Harmony Biosciences in a report on Thursday, October 15th. They issued a “buy” rating and a $55.00 price objective for the company. Needham & Company LLC restated a “buy” rating and set a $50.00 target price on shares of Harmony Biosciences in a report on Monday, October 19th. Wolfe Research started coverage on Harmony Biosciences in a report on Wednesday, August 26th. They set an “outperform” rating and a $60.00 target price on the stock. Weiss Ratings raised Harmony Biosciences from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Monday, October 12th. Finally, Zacks Research upgraded Harmony Biosciences from a “hold” rating to a “strong-buy” rating in a research note on Thursday, October 15th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $48.00.

Read Our Latest Research Report on Harmony Biosciences

Insider Activity

In other news, insider Kumar Budur sold 35,852 shares of the business’s stock in a transaction dated Friday, September 18th. The shares were sold at an average price of $43.05, for a total transaction of $1,543,428.60. Following the transaction, the insider owned 13,115 shares in the company, valued at approximately $564,600.75. The trade was a 73.22% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In the last quarter, insiders have sold 72,406 shares of company stock worth $3,108,520. Insiders own 11.00% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Farther Finance Advisors LLC boosted its stake in shares of Harmony Biosciences by 166.7% in the 3rd quarter. Farther Finance Advisors LLC now owns 816 shares of the company’s stock valued at $32,000 after purchasing an additional 510 shares in the last quarter. Nykredit A S bought a new stake in shares of Harmony Biosciences in the 2nd quarter worth about $33,000. Signature Equity Partners LLC bought a new stake in shares of Harmony Biosciences in the 3rd quarter worth about $37,000. Integrated Wealth Concepts LLC acquired a new stake in shares of Harmony Biosciences during the 2nd quarter worth about $65,000. Finally, Signaturefd LLC increased its position in shares of Harmony Biosciences by 200.0% during the 3rd quarter. Signaturefd LLC now owns 1,686 shares of the company’s stock worth $66,000 after purchasing an additional 1,124 shares in the last quarter. 86.23% of the stock is owned by institutional investors.

Harmony Biosciences Stock Down 6.9%

The firm has a market cap of $2.01 billion, a price-to-earnings ratio of 11.19, a PEG ratio of 0.30 and a beta of 1.00. The business’s 50-day moving average is $39.64 and its 200-day moving average is $34.73. The company has a debt-to-equity ratio of 0.13, a quick ratio of 3.45 and a current ratio of 3.48.

Harmony Biosciences Company Profile

(Get Free Report)

Harmony Biosciences Holdings, Inc is a commercial-stage biopharmaceutical company focused on developing and providing therapies for patients with rare neurological disorders. The company’s activities center on conditions involving sleep-wake regulation and other central nervous system disorders where treatment options may be limited.

Harmony’s principal product is WAKIX (pitolisant), an oral, non-scheduled treatment that acts as a histamine-3 receptor antagonist/inverse agonist. In the United States, WAKIX is approved for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy and for excessive daytime sleepiness in pediatric patients aged 6 and older with narcolepsy.